Investigation Report on China Menotropins Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333486|
|出版日期||內容資訊||英文 30 Pages
|Menotropins的中國市場分析 Investigation Report on China Menotropins Market, 2010-2019|
|出版日期: 2015年06月18日||內容資訊: 英文 30 Pages||
根據統計資料，中國國內的生產適齡期人口 (20∼29歲的女性人口) 為1億人，其中的12％以上有不孕症煩惱。因為不孕症患者的約30％原因被認為是排卵抑制，排卵抑制的潛在患者可能有360萬人以上。Menotropins在誘導排卵中是最古老的之一，1960年代已經在臨床現場使用。近幾年中國國內Menotropins的需求也急速擴大，2005年達2000萬人民幣的市場規模，以22.8％的年複合成長率(CAGR) 持續增加，2014年達7910萬人民幣。
According to the statistics, at present there are about 100 million women in the high-fertility period (aged 20-29) in China, over 12% of whom suffer from infertility. About 30% of female diagnosed with infertility suffer from ovulation inhibition. Herein it can be estimated that the number of potential patients suffering from ovulation inhibition is larger than 3.6 million. Popular clinic drugs utilized in the treatment of ovulation inhibition include clomifene citrate, and gonadotropin (mainly classified into follicle stimulating hormone, menotropins and chorionic gonadotrophin). Gonadotropin is usually utilized if clomifene citrate doesn't work , and sometimes utilized together with clomifene citrate to promote ovulation. chorionic gonadotrophin in combination with follicle stimulating hormone or menotrophins are often applied in the clinic . That is to say,, follicle stimulating hormone or menotrophins is utilized first to foster the growth and maturation of follicle, and then chorionic gonadotrophin is utilized to stimulate ovulation and provide luteal support.
As one of the earliest ovulation stimulants utilized in the clinic , menotropins was utilized in the clinic as early as the 1960s. Extracted from urines of post-menopausal women, menotropins is mainly composed of 75IU ovulation stimulant and 75IU luteinizing hormone. It fosters the growth and maturation of ovulation and affiliates secretion of estrogen within the follicle. In China, there are plenty of manufacturers of menotropins. However, the quality of menotropins produced by these manufacturers is uneven. Menotropins produced by Livzon Pharmaceutical Group Inc, with high purity and outstanding quality, enjoys individual pricing of the development and reform committee, thus its bidding price is slightly higher than that of other manufacturers.
Menotropins has been growing at a rapid pace after entering the Chinese market, with its annual sales value rising from less than CNY 20 million in 2005 to CNY 79.1 million in 2014 and its CAGR from 2005 to 2014 reaching 22.8%. Chinese menotrohins market is mainly dominated by Livzon Pharmaceutical, Livzon Pharmaceutical Group, Inc, Ferring Pharmaceytical Co., Ltd (Germany), Ma'anshan Fengyuan Pharmaceutical Co., Ltd, Yantai North Pharmaceutical Co., Ltd and Shanghai Livzon Pharmaceutical Co., Ltd, among which Shanghai Livzon Pharmaceutical Co., Ltd owns the largest market share, market share for sales value exceeding 60% in 2004.
Readers can have access to the following information through this report:
The author suggests the following groups of people purchase this report: